NCT06996756View on ClinicalTrials.gov

Gene Therapy for Alpha-1 Antitrypsin Deficiency

PHASE1RecruitingINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2032

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

BIOLOGICAL

AAV8hAAT(AVL)

AAV8hAAT(AVL) gene transfer vector

Trial Locations (1)

10021

RECRUITING

WCMC Department of Genetic Medicine, New York

All Listed Sponsors

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Weill Medical College of Cornell University

OTHER